Kailera Therapeutics Inc. (NASDAQ:KLRA) is one of the best IPO stocks with huge upside potential.
On July 7, Kailera Therapeutics announced positive topline results from two Phase 3 clinical trials conducted by Hengrui Pharma for HRS-7535/KAI-7535, an oral small-molecule GLP-1 receptor agonist
In the obesity trial, participants achieved a mean weight loss of up to 10.9% by Week 44 and 11.1% by Week 50, while the type 2 diabetes trial demonstrated a mean HbA1c reduction of 1.50% to 1.68%. Liver safety findings across both trials remained consistent with prior data, showing no observed safety signals. These results underscore the potential for the oral treatment to offer a convenient and scalable alternative for patients, maintaining efficacy while providing a favorable safety profile.
Concurrent with these developments, Kailera Therapeutics Inc. (NASDAQ:KLRA) is advancing KAI-7535 through a global Phase 2 clinical trial that began in April 2026. This study aims to further optimize the drug’s clinical profile for obesity treatment by assessing a broad range of doses and titration strategies, with results expected in 2027. Kailera Therapeutics Inc. (NASDAQ:KLRA) is a clinical-stage biotechnology company dedicated to advancing a diversified pipeline of obesity treatments, including four clinical-stage candidates.